{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:55Z","timestamp":1790856415941,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2026.106062","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:51:14Z","timestamp":1769500274000},"page":"106062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-5753","authenticated-orcid":false,"given":"P.","family":"Filis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Filis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-9987","authenticated-orcid":false,"given":"T.","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.esmoop.2026.106062_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.neo.2015.09.001","article-title":"Confirmatory trials in the evaluation of anticancer medicinal products in man \u2013 PFS2: a measure of therapeutic action-at-a-distance","volume":"17","author":"Oronsky","year":"2015","journal-title":"Neoplasia"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106062_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib3","first-page":"22","article-title":"Translating cancer trial endpoints into the language of managed care","volume":"5","author":"Kogan","year":"2008","journal-title":"Biotechnol Healthc"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106062_bib4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106062_bib5","article-title":"Validity and efficiency of progression-free survival-2 as a surrogate end point for overall survival in advanced cancer randomized trials","volume":"8","author":"Woodford","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106062_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","article-title":"Drug rechallenge and treatment beyond progression \u2013 implications for drug resistance","volume":"10","author":"Kuczynski","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106062_bib9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.34085","article-title":"The validity of progression-free survival 2 as a surrogate trial end point for overall survival","volume":"128","author":"Woodford","year":"2022","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106062_bib10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","article-title":"Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer","volume":"99","author":"Sherrill","year":"2008","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106062_bib11","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","article-title":"Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer","volume":"26","author":"Burzykowski","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106062_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.106062_bib13","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.esmoop.2026.106062_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.esmoop.2026.106062_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106062_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s guide to correlation coefficients","volume":"18","author":"Akoglu","year":"2018","journal-title":"Turk J Emerg Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106062_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8042","key":"10.1016\/j.esmoop.2026.106062_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106062_bib20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106062_bib21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"10371","key":"10.1016\/j.esmoop.2026.106062_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"10390","key":"10.1016\/j.esmoop.2026.106062_bib23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.106062_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","article-title":"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study","volume":"168","author":"Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106062_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106062_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106062_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"New Engl J Med"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106062_bib30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106062_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106062_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106062_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-013-2828-z","article-title":"A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer","volume":"143","author":"Janni","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106062_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/JCO.2024.42.16_suppl.1003","volume":"42","author":"Juric","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.106062_bib35","article-title":"183MO Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+\/HER2- advanced breast cancer (ABC): second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106062_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106062_bib37","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106062_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106062_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial","volume":"200","author":"Di\u00e9ras","year":"2024","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106062_bib41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106062_bib42","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106062_bib43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106062_bib44","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdw316","article-title":"Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent\/metastatic breast cancer","volume":"27","author":"Vrdoljak","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106062_bib45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.breast.2015.08.005","article-title":"Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer","volume":"24","author":"Janni","year":"2015","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106062_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.esmoop.2026.106062_bib47","series-title":"Institute for Quality and Efficiency in Health Care: Executive Summaries. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG)","article-title":"Validity of surrogate endpoints in oncology: executive summary of rapid report A10-05, Version 1.1","year":"2005"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106062_bib48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jval.2017.09.010","article-title":"Effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany","volume":"21","author":"Isbary","year":"2018","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106062_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","article-title":"Methods for adjusting for bias due to crossover in oncology trials","volume":"32","author":"Ishak","year":"2014","journal-title":"Pharmacoeconomics"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:29:58Z","timestamp":1771864198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702926000049"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106062","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106062"}}